Sodium Oligomannurarate

甘露特钠

Report date: 2026/03/04 15:25:36
NMEFirst In Class

Base Information

Drug NameSodium Oligomannurarate
Drug Alias NameSodium Oligo-mannurarate甘露特钠Hamput SodiumMannut SodiumNine Phase One +[9] 
ClassificationNatural product/Extract
Mechanisms of ActionBeta amyloid A4 protein inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsCognition DisordersAlzheimer Disease
Global Approved IndicationsAlzheimer Disease
Approved Indications in ChinaAlzheimer Disease
Original Approved Country/TerritoryMainland China
Original Approved Date2019/11/02
Country/TerritoryCzechiaCanadaUnited States +[14] 
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaWithdrawn
Originator CompaniesOcean University Of ChinaShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesGreen Valley (Shanghai) Pharmaceutical Technology Co LtdShanghai Greenvalley Pharmaceutical Co LtdOcean University Of China
Active IndicationsN/A
Inactive IndicationsCognition DisordersAlzheimer Disease

Other Information

ATC CodeN07
Related LinksN/A